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Abstract
As the major storage site for triglycerides and free cholesterol, adipose tissue plays a central role in energy
metabolism. ApoA-I is the main constituent of HDL and plays an important role in removal of excess cholesterol
from peripheral tissues. Recently, multiple studies have shown beneficial effects of apoA-I on adipose metabolism
and function. ApoA-I was reported to improve insulin sensitivity and exert anti-inflammatory, anti-obesity effect in
animal studies. Interestingly, Uptake and resecretion of apoA-I by adipocytes has been detected. However, the
significance of apoA-I recycling by adipocytes is still not clear. This article reviewed methods used to study cellular
recycling of apoA-I and summarized the current knowledge on the mechanisms involved in apoA-I uptake by
adipocytes. Since the main function of apoA-I is to mediate reverse cholesterol transport from peripheral tissues,
the role of apoA-I internalization and re-secretion by adipocytes in intracellular cholesterol transport under
physiological and pathological conditions were discussed. In addition, findings on the correlation between apoA-I
recycling and obesity were discussed. Finally, it was proposed that during intracellular transport, apoA-I-protein
complex may acquire cargoes other than lipids and deliver regulatory information when they were resecreted into
the plasma. Although apoA-I recycling by adipocytes is still an unsolved mystery, it’s likely that it is more than a
redundant pathway especially under pathological conditions.
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Background
Apolipoprotein A-I (apoA-I) is synthesized and secreted by
the liver and intestine. As the major protein constituent of
high-density lipoprotein (HDL), apoA-I plays an important
role in reverse cholesterol transport from peripheral tissues
to the liver [1]. As the body’s largest reservoir of free chol-
esterol, adipose tissue contributes to apoA-I lipidation and
nascent HDL biogenesis [2, 3]. On the other side, apoA-I
has been reported to have reciprocal effects on adipose tis-
sue metabolism and function. For example, apoA-I has
been reported to promote glucose uptake [4], improve insu-
lin sensitivity [5], upregulate the expression of adiponectin
[6], and exert anti-inflammatory effect [7, 8]. It is generally
accepted that the multiple effects of apoA-I is mediated
through regulation of lipid raft or direct binding with sur-
face receptors, resulting in subsequent activation of intra-
cellular signaling [9, 10]. What is interesting is our previous
finding that apoA-I protein was found in human adipose
tissue while apoA-I mRNA was not detected, indicating
that apoA-I found in adipose tissue was exogenous. Actu-
ally, cellular internalization of apoA-I has been observed in
several cell lines, including macrophages, endothelium and
smooth muscle cells [11–13]. However, it is not until recent
years that the uptake and resecretion of apoA-I by adipo-
cytes has been confirmed with the significance still
remaining unclear [14, 15]. This article briefly discussed
methods used to study apoA-I recycling, mechanisms for
apoA-I internalization and the possible significance of
apoA-I recycling by adipocytes.
ApoA-I-induced cell signaling and adipocyte metabolism
Except for mediating reverse cholesterol transport, there
are several well documented evidence suggesting that
apoA-I could regulate cellular function of adipocytes.
ApoA-I has been reported to exert anti-inflammatory ef-
fect on adipocytes. ApoA-I reduced monocyte chemo-
tactic protein-1 (MCP-1) and serum amyloid A3 (SSA3)
expression and attenuated reactive oxygen species (ROS)
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through diminishing the translocation of NADPH oxi-
dase (nicotinamide adenine dinucleotide phosphate-
oxidase) into lipid rafts [7]. In vitro study showed that in
cultured 3T3-L1 adipocytes apoA-I upregulated the ex-
pression of adiponectin in phosphatidylinositol 3-kinase
(PI3K)-dependent manner [6]. In brown adipocytes,
apoA-I upregulated the expression of uncoupling protein
1, which participated in the control of energy expend-
iture, possibly involved Adenosine 5‘-monophosphate-
activated protein kinase (AMPK) signaling activation
[16]. It is so far generally accepted that the multiple effect
of apoA-I are results of intracellular signaling cascade trig-
gered either through a direct interaction between apoA-I
and surface receptors such as ATP-binding cassette trans-
porter A1 (ABCA1) and β subunit of ATP synthase (β-
ATPase) [17–19] or through lipid raft disruption resulted
from apoAI-ABCA1 complex induced cholesterol efflux [9,
10]. Although the phenomenon of apoA-I internalization
has been observed in vascular cells such as macrophage
and endothelium, the physiological significance remains un-
determined. Besides, uptake and resecretion of apoA-I by
adipocytes has only been demonstrated in recent years.
Methods to study the recycling of ApoA-I by adipocytes
Studies in intracellular transport of lipoproteins demand
specific and robust labeling of the target entity with
minimal alteration of the investigated transport process
by the labeling strategy. To achieve this goal, recombin-
ant apoA-I needs to be constructed so that the modified
apoA-I can bind with the labeling probe without affect-
ing its main biological properties. Pulse-chase experi-
ments of isotope- or fluorescence-labeled proteins are
the usual approach used to gather dynamic information
about apoA-I internalization and resecretion. Confocal
studies of labeled apoA-I and labeled markers of specific
organelles or proteins can give information about apoA-
I localization and possible interaction with other
proteins.
Fluorescent labeling was used to address the cellular
uptake of apoA-I, which relies on labeling of a recom-
binant form of apoA-I with a fluorescent probe at a sin-
gle and highly targeted site in the molecule without
altering the main function of apoA-I (the ability to
promote cholesterol efflux). Because human apoA-I
ordinarily lacks a cysteine, which is necessary for a
thiol-reactive probe (e.g. agent Alexa Fluor 546 C5-
maleimide) to de attached, recombinant forms of apoA-
I needs to be constructed. Cys residue needs to be
introduced without affecting the ability of apoA-I to
promote cholesterol efflux.
In humans, apoA-I is synthesized in the liver and
intestinal cells as a non-glycosylated pre-pro-protein
[20]. The 18 amino acid pre-segment is removed be-
fore the protein leaves the cell whilst the 6 amino
acid pro-segment is cleaved during post secretion,
leaving the mature 243 amino acid protein [21].
Since apoA-I is non-glycosylated, bacterial expression
system such as Escherichia coli is usually the pre-
ferred option because eukaryotic systems (e.g. Chin-
ese hamster ovary cell system, CHO) are generally
more difficult to transfect than bacteria. Besides,
once successfully transfected, CHO cell colonies
must undergo an in-depth screening process to find
stably transfected, high expression colonies. In
addition, eukaryotic cells require a longer period of
time for expression and a much higher level of
maintenance than bacteria. However, if the pro-
segment of apoA-I was removed, expression level in
Escherichia coli would be very low unless one modi-
fies the existing DNA sequence for the first 8 amino
acid to a sequence in which bacterial codons are
more readily available [22]. Therefore, fusion pro-
teins containing a histidine tag which can be purified
over a nickel chelating column have been created for
the purpose of both expression and purification. Be-
fore using these expression products in experiments,
the His tag sequence needs to be proteolytically
cleaved away from the target sequence because it
may adversely affect both structure and function of
the apoA-I. Enteropeptides [23], factor Xa [24], and
thrombin [25] are often used proteolytic systems and
work well for many proteins. However, their use for
apolipoprotein systems are limited by the fact that
these proteases often cut at locations within the tar-
get protein in addition to the intended site engi-
neered between the fusion and target proteins. In
the case of apoA-I, this problem has been circum-
vented by lipidating the protein before cleavage,
masking the secondary cleavage sites through a con-
formational change [26]. Another method to address
this problem was IgA protease system. It was found
that IgA protease from Neisseria gonorrhoeae did not
cleave the wild type apoA-I sequence [27]. There-
fore, adding an Igase site to the pET30 expression
vector containing the apoA-I cDNA, IgA protease
cleaved the His-tag without affecting the target
apoA-I product [27]. As an alternative to protease-
dependent removal of the N-terminal His-Tag, an
acid labile Asp-Pro peptide bond was introduced
into the apoA-I sequence between amino acids 2 and
3 of the wild type apoA-I sequence, which was
achieved by mutating Glu2 to Asp, taking advantage
of the presence of the Pro at position 3 in wild type
apoA-I. Formic acid could efficiently cleave the
apoA-I His-Tag at this acid labile peptide bond
without exerting discernable effect on the apoA-I
product, presenting as an efficient way for protein
purification [28]. Fluorescent microscopy studies
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were then used to follow the cell biology of fluores-
cent labeled apoA-I.
Although fluorescent microscopy is well suited for
measuring fluorescent apoA-I internalization, it gives little
information on the fate of the label after internalization.
Therefore, pulse-chase experiment through radiolabeled
apoA-I could be used to study the fate of the internalized
protein. Because nonspecific radioiodination of apoA-I
can have significant effect on its structure and metabolism
[29], endogenous labeling of wild-type apoA-I expressed
in methionine auxotrophline line of bacteria (E. coli) by
35S-methionine is nowadays a commonly accepted
method [12].
Although approaches based on the use of fluorescent
labeled or radiolabeled apoA-I are highly valuable to
study lipoprotein uptake, it is necessary to realize that
there are some limitations due to unspecific labeling of
cellular compartment caused by partial degradation of
apoA-I followed by release of the small labeling probe.
Besides, there is difficulty in distinguishing cellular in-
corporation of the protein from protein absorption to
plasma membrane.
To solve the problem, a method was developed which
could provide an unambiguous proof of apoA-I recycling
by adipocytes through creating a functional recombinant
apoA-I containing a phosphorylation site (pka-apoA-I),
which could be recognized by the catalytic subunit of
cAMP-dependent protein kinase (PKA) [15]. Because
cellular uptake of the protein would allow its phosphor-
ylation and the phosphorylated protein would be found
in the cell culture medium if re-secreted, phosphorylated
apoA-I in the medium was correlated to the extent of
apoA-I recycling. pka-apoA-I construct was prepared by
sub-cloning the full-length sequence of mature human
apoA-I into a commercial vector that incorporated an
N-terminal tag encoding for a six-His tag and a five
amino acid recognition sequence (RRASV) for the cata-
lytic subunit of PKA. Adipocytes were pre-incubated
with 32P-phosphate to radiolabel the cellular pool of
ATP. Phosphorylated apoA-I collected from the culture
medium after different times of incubation with pka-
apoA-I were subjected to SDS-PAGE, followed by coo-
massie blue staining and autoradiography to analyze the
recycling of apoA-I by adipocytes [14, 15].
Mechanism of ApoA-I uptake by adipocytes
Receptor mediated process
ApoA-I entering into adipocytes may be a receptor me-
diated process or the result of nonspecific endocytic
membrane invagination. In line with several other cell
types [12], a receptor mediated process was supported
by the results that the content of phosphorylated pka-
apoA-I in the culture medium, which represented the
rate of apoA-I recycling, increased in response to
increase in concentration of recombinant apoA-I (pka-
apoA-I) and approached a plateau at concentrations
higher than 75μg/ml. Besides, human apoA-I purified
from plasma reduced apoA-I recycling in a dose
dependent manner, indicating a competition between
human and recombinant apoA-I for binding to a com-
mon receptor [14].
Clathrin
While LDL endocytosis occurs via clathrin-coated pits
[30], it is unclear whether apoA-I internalization is cla-
thrin dependent. It was shown that blocking clathrin-
mediated endocytosis by its specific inhibitor monodan-
syl cadaverine (MDC) abolished apoA-I internalization
into macrophage (RAW and THP-1 cell), suggesting up-
take of apoA-I by macrophages is clathrin-dependent
[13, 31]. However, considering heterogeneity may exist
between different tissues and cell lines, further study
need to be carried out to clarify if clathrin-pathway is in-
volved in apoA-I uptake by adipocytes.
Caveolae
Caveolae, implicated in a variety of physiological process
including cell signaling and endocytosis, are curved lipid
raft regions rich in cholesterol and sphingolipids [32].
Caveolin-1, which is the main protein constituent of ca-
veolae, has been shown to interact with ABCA1 and is
involved in cholesterol efflux to apoA-I in several cell
types [33]. Direct interaction of caveolin-1 with apoA-I
has also been reported. Mouse embryonic fibroblasts
(MEFs) derived from wild type animals were reported to
have 2.6-fold more apoA-I binding sites than MEFs de-
rived from caveolin-1 deficient animals. In addition,
caveolin-1 binding with apoA-I was reported to target
apoA-I for internalization [34]. Considering the remark-
ably abundant caveolae on the surface of adipocytes
which accounts for 50 % of the surface area [32], it is
speculated that caveolae may be involved in apoA-I up-
take by adipocytes. Whether caveolae is pre-requisite for
apoA-I internalization and whether the presence of cave-
olae accounts for a favorable environment for apoA-I in-
ternalization warrant further study.
ABCA1 independent process
Because apoA-I could directly bind with ABCA1 which
rapidly shuttles between intracellular compartment and
plasma membrane [35], whether apoA-I internalization
is ABCA1 dependent has been explored. Previous studies
which focused on macrophages observed co-localization
of apoA-I and ABCA1 in endosomal compartment
[36–38], supporting the idea that ABCA1-apoA-I
complex were delivered to intracellular compartment
where it received lipids and formed a nascent-HDL
like particles that were subsequently secreted from
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the cell. However, a recent study carried out in adipo-
cytes showed that Brefeldin A (BFA), which inhibited
vesicular trafficking of ABCA1, didn’t affect apoA-I
recycling by adipocytes, suggesting an ABCA1 inde-
pendent way for apoA-I uptake may exist [14].
Mediated by β-ATPase
β-ATPase mainly presents in mitochondria membrane
and is the terminal enzyme of the oxidative phosphoryl-
ation pathway. Unexpectedly, ectopic localization of β-
ATPase on cell surface were found in several cells types
including hepatocytes and adipocytes. What’s intriguing
is that β-ATPase has been characterized as a receptor
for apoA-I [15, 17, 39]. The binding of apoA-I to β-
ATPase induced ATP hydrolysis and promoted extracel-
lular ADP generation, which in turn stimulated intracel-
lular signaling by activating purinergic receptors, which
belong to the family of G-Protein-coupled receptors
stimulated by extracellular nucleotides. In hepatocytes, it
was demonstrated the interaction of the β-ATPase with
apoA-I modulated HDL endocytosis [17, 40]. Niacin,
which is used to raise plasma levels of HDL, has been
shown to reduce the ectopic expression of the β-ATPase
in hepatocytes and inhibit cellular uptake of HDL [41].
In adipocytes, β-ATPase has been proven to be involved
in apoA-I uptake, evidenced by the fact that apoA-I re-
cycling was blocked by a monoclonal antibody against
the β-ATPase [15].
Regulation of apoA-I internalization through cAMP-PKA
signaling
Previous studies revealed that the interaction between
apoA-I and ABCA1 activated adenylate cyclase and in-
creased the content of cAMP [42]. cAMP/protein kinase
A (PKA) were reported to play an important role in
regulating apoA-I/ABCA1-induced lipid translocation
and removal. Pharmacologic modulation to decrease
cAMP levels and PKA activity led to reduction in apoA-
I-ABCA1 mediated cholesterol efflux [43, 44]. Con-
versely, interference to activate cAMP/PKA signaling el-
evated apoA-I-induced cholesterol efflux [44]. The
molecular mechanisms may include: 1) regulation of
ABCA1 expression by cAMP/PKA signaling at the tran-
scriptional level [42], 2) phosphorylation of ABCA1 by
PKA may result in altering the conformation of the pro-
tein to a more active state for lipid translocation across
the cell membrane [45]. However, an interesting
phenomenon was observed in the murine macrophages
RAW 264 cell that cholesterol efflux to apoA-I was ab-
sent in the absence of cAMP but inducible by cAMP an-
alogues 8-Br-cAMP [31, 46]. Coincidently, compared
with cAMP treatment, cellular uptake and resecretion of
apoA-I was apparently much less in the basal condition
when cAMP is absent [31, 46]. Based on these
interesting findings, it was queried was cellular internal-
ization of apoA-I pre-requisite for apoA-I-induced chol-
esterol efflux or were they just two independent events
subsequent to apoA-I binding with surface receptor?
Based on previous studies carried out in macrophages, it
is generally accepted that the contribution of internal-
ized apoA-I to cholesterol efflux and HDL formation
seems to be limited [12, 47].
In adipocytes, cAMP/PKA signaling was demonstrated
to regulate apoA-I recycling. Stimulation with iso-
proterenol, which raised cAMP and activated PKA, ac-
celerated recycling of apoA-I by 3 T3-L1 adipocytes.
PKA inhibitor H89 inhibited the internalization and
resecretion of apoA-I [14, 15]. The molecular mechan-
ism underlying the regulatory effect of cAMP-PKA sig-
naling on the recycling of apoA-I by adipocytes remains
unclear. Whether PKA would regulate the binding abil-
ity of apoA-I with surface β-ATPase, which is involved
in mediating apoA-I internalization, is not known. In
addition, whether PKA may regulate the expression of
β-ATPase or its translocation to the plasma membrane
need to be further investigated.
Physiological role of ApoA-I internalization in adipocytes
ApoA-I internalization and adipocyte cholesterol efflux
The physiological significance of apoA-I internalization
in adipocytes is not known. As mentioned above, the
mechanism of lipid-free apoA-I lipidation is not fully
understood yet and whether apoA-I lipidation may re-
quire its internalization remains controversial. Some
studies supported the idea that apoA-I lipidation mainly
occurred at the cell surface. A model by Phillips pro-
posed that ABCA1 shuttled phospholipids from the
inner to extracellular surface of the plasma membrane,
resulting in membrane bulges with high curvature that
were sufficient to allow apoA-I penetration. Once apoA-
I bound to ABCA1 on the cell surface and was lipidated,
the N-terminus of apoA-I was unfolded and formed an
unstable intermediate structure that was rapidly released
from the cell [48, 49]. On the other hand, other studies
reported that apoA-I internalization was involved in
apoA-I induced cholesterol efflux. In previous reported
studies, RAW cells were cholesterol loaded, incubated
with apoA-I and treated with 8-Br-cAMP to stimulate
the take up of apoA-I. After indicated period of treat-
ment, apoA-I was depleted from the culture medium
through washing. Significant cAMP-dependent [3H]-
cholesterol efflux was detected during chase period even
in the absence of exogenous apoA-I and HDL in the cul-
ture medium. Besides, the degree of cholesterol efflux
was positively correlated to the extent of apoA-I intern-
alization, indicating cholesterol efflux detected in this
study was due to re-secretion of the internalized and
lipidated apoA-I [31].
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As the body’s largest pool of free cholesterol, adipose
tissue was demonstrated to release cholesterol and con-
tribute to HDL biogenesis [2, 3, 50]. Is apoA-I internal-
ization involved in adipocytes cholesterol release? First
of all, internalization of apoA-I is not indispensable for
adipocytes cholesterol release because blocking apoA-I
internalization does’t have a significant effect on choles-
terol efflux [15]. However, it is worth noting that under
basal condition cellular uptake of apoA-I is limited.
Therefore, it may be more appropriate to consider the
significance of apoA-I internalization under circum-
stances when the degree of apoA-I internalization is
more prominent.
Intracellular cholesterol transport during cholesterol
mobilization
It is interesting to note that both apoA-I internalization
and adipocyte lipolysis are stimulated by PKA activation.
Multiple evidence suggested that cholesterol and trigly-
ceride homeostasis were coupled in adipocytes [51, 52],
which led to the question what the role of apoA-I in
intracellular cholesterol transport during lipid
mobilization may be. Adipose is the body’s largest pool
for free cholesterol. In adipocytes, <6 % cholesterol
stored is in the esterified from [53, 54], which is different
from other cell type [55]. Surface layer of lipid droplet
was identified as primary intracellular storage site for
free cholesterol within adipocytes [56]. It was shown in
3 T3-L1 adipocytes that under basal conditions choles-
terol mobilization from adipocytes onto apoA-I was very
limited despite induction of ABCA1 expression. How-
ever, under conditions of sustained lipolytic stimulation,
a boost in the mobilization of adipocyte cholesterol was
observed [52]. Besides, stimulation of lipolysis is accom-
panied by an increased cholesterol transport from sur-
face of lipid droplet to plasma membrane (PM) where
cholesterol can be removed [51]. Generally, there are
vesicular and nonvesicular ways through which the
highly hydrophobic free cholesterol can be transported
from the lipid droplet pool to PM-pool. Cholesterol
could be present in the membrane of intracellular vesi-
cles for trafficking, which requires intact cytoskeleton
and ATP to provide moving tracks and energy. Nonvesi-
cular transport is mediated by diffusible carrier proteins,
which have hydrophobic cavities to bind cholesterol and
transport it across the aqueous cytosol [57, 58]. Choles-
terol, together with phospholipids and proteins, were re-
ported to be incorporated into cytosolic lipid protein
particles (CLPP) which were HDL-like cytosolic lipid-
protein complex with density of 1.09-1.16 g/ml and di-
ameters of 17-18 nm [59]. In order to transport choles-
terol to the target cellular compartment, the cholesterol
transfer protein in CLPP needs to contain a specific
membrane contact site. For example, intracellular
transport from late endosome to mitochondria involves
steroidogenic acute regulatory (StAR) protein on the
mitochondria and cholesterol donating StAR-related
lipid transfer (START) domain protein 3 (StARD3) on
late endosomes [60, 61]. In the case of cholesterol trans-
port from the ER (endoplasmic reticulum) to Golgi,
cholesterol transport depends on the activity of oxysterol
binding protein (OSBP) to create membrane contact
sites between both organelles [62, 63]. What’s interesting
is that caveolin-1, a critical protein found in membrane
domain caveolae, has been found as protein constituent
of CLPP. Since direct interaction of apoA-I with
caveolin-1 has been confirmed at the cell surface [34], it
would be interesting to study intracellular interaction of
these two proteins and its possible role in intracellular
cholesterol transport. It is speculated that intracellular
apoA-I may be involved in CLPP formation, facilitating
intracellular cholesterol transport to plasma membrane
for further removal through efflux pathway. Therefore,
apoA-I internalization and resecrestion by adipocytes may
be accompanying process of cholesterol mobilization and
represent an alternative pathway to maintain cholesterol
homeostasis.
Relevance to obesity
Recently, the possible anti-obesity effect of apoA-I has
triggered great interest. In mouse models, apoA-I trans-
genic mice had significant lower fat content than wild
type mice after feeding with high fat diet for three
months [16]. In other studies, daily administration of
apoA-I mimetics D-4 F and L-4 F in high fat diet fed
mice reduced weight gain and decreased obesity when
compared with age-matched vehicle-treated obese mice
[5, 64]. Several studies demonstrated that apoA-I may
contribute to modulating body fat content by controlling
the extent of lipolysis [5, 65]. Recent study showed that
the naturally occurring apoA-I variant Milano, which
contains a single point mutation that lead to an Arg
(173) Cys substitution, reduced fat mass through stimu-
lation of lipolysis. Similar to apoA-I WT, the anti-obesity
effect of Milano was independent of ABCA1 nor the ca-
nonical cAMP/PKA signaling pathway [66]. Interest-
ingly, the Milano-stimulated lipolysis was much greater
compared with apoA-I WT [66]. Since apoA-I Milano
was demonstrated to be more efficient in modulating
cholesterol efflux than apoA-I WT [67], this finding fur-
ther supported the notion that cholesterol mobilization
was coupled with lipolysis. It would be interesting to fur-
ther investigate the significance of adipocytes apoA-I re-
cycling in obesity.
Ectopic expression of β-ATPase on the plasma mem-
brane of adipocytes was demonstrated to be involved in
mediating the endocytosis and re-secretion of apoA-I
[15]. Interestingly, the ectopic expression of β-ATPase
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was found to be increased during adipogenesis [68].
However, the physiological significance of β-ATPase in
adipogenesis is not known. Our preliminary study ob-
served that apoA-I could regulate adipocyte differenti-
ation with a mechanism which is not clear. Therefore,
further studies should be carried out to investigate
apoA-I recycling at different stage of adipogenesis.
Whether apoA-I recycling is involved in adipogenesis is
an interesting question for further exploration.
Transport of cellular miRNA
It has been reported recently that HDL can transport
microRNAs [69], which are short non-coding regulatory
RNAs that modulate biological homeostasis by control-
ling gene expression through mRNA target and transla-
tional repression. Circulating miRNAs can be
transported from donor cells to recipient cells and are
viewed as a new class of biomarkers for a diverse set of
diseases [70]. As the main protein component of HDL,
apoA-I has been used for the systemic and specific deliv-
ery of small interfering RNA (siRNA) to hepatocytes in
animal models [71]. It is interesting to hypothesize that
apoA-I might acquire microRNAs during intracellular
trafficking in adipocytes and deliver regulatory informa-
tion to recipient cells when it is re-secreted into the
plasma.
Summary
To sum up, uptake and resecretion of apoA-I by adipo-
cytes were detected by using different apoA-I-labeling
methods. Current studies on the mechanisms of apoA-I
uptake by adipocytes support that it is a receptor medi-
ated process which is ABCA1 independent but involves
β-ATPase ectopically expressed on the plasma mem-
brane. Besides, cAMP/PKA signaling regulates recycling
of apoA-I by adipoctes, with the underlying mechanisms
remain unclear. Whether apoA-I internalization is a cla-
thrin and caveolae dependent process needs to be fur-
ther studied. Although apoA-I recycling by adipocytes
does not seem to play a major role in regulating adipose
cholesterol metabolism under physiological conditions,
it is likely that apoA-I recycling becomes important in
pathological conditions when cholesterol mobilization is
stimulated. Because cholesterol and TG metabolism are
coupled in adipose tissue and recent recognition of the
relationship between apoA-I and obesity, the physio-
logical relevance of apoA-I recycling to obesity and adi-
pogenesis are interesting questions to be answered.
During intracellular transport, apoA-I may function as a
vehicle through interaction with other proteins. The
cargo is not restricted to intracellular cholesterol but
may also include miRNAs, which modulate gene expres-
sion of target cells when apoA-I-miRNAs complex are
re-secreted into the circulation by adipocytes.
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